180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
14 March 2024 - 11:30PM
180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the
“Company”), today announced that the Company received a letter on
March 13, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”)
indicating that the Company has regained full compliance with the
minimum bid price for continued listing on the Nasdaq pursuant to
Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price
Requirement”).
As indicated in the letter, Nasdaq determined
that for 10 consecutive business days, the closing bid price of the
Company’s common stock was at or above $1.00 per share.
Accordingly, the Company has regained compliance with the Minimum
Bid Price Requirement.
About 180 Life Sciences
Corp.
180 Life Sciences Corp. is a clinical stage
biotechnology company focused on the development of therapeutics
for unmet medical needs in chronic pain, inflammation and fibrosis
by employing innovative research, and, where appropriate,
combination therapy. The Company’s current primary focus is a novel
program to treat several inflammatory disorders using anti-TNF
(tumor necrosis factor).
Investors:
Jason AssadDirector of IR180 Life Sciences
CorpJason@180lifesciences.com
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Nov 2024 to Dec 2024
180 Life Sciences (NASDAQ:ATNF)
Historical Stock Chart
From Dec 2023 to Dec 2024